Cell: Chinese scientists have structurally revealed that BD-368-2 antibodies can effectively treat hamsters severely infected with the new coronavirus.

September 24, 2020 /--- Understanding how powerful meso-antibodies (NAbs) inhibit SARS-CoV-2 is key to developing effective therapies.
In a new study, using expertise in single-cell genomics, Xie Xiaoliang of Peking University's Beijing Future Genetic Diagnostics High-Sharp Innovation Center, in collaboration with researchers at Beijing You'an Hospital, affiliated with Capital Medical University, collected blood samples from more than 60 recovery patients, and in those blood samples, 14 high-acting medium and antibodies were selected from 8,558 antigen-binding IgG1-clone (clonotype) 2020, doi:10.1016/j.cell.2020.05.025).
as their most powerful antibody, BD-368-2 has IC50 values of 8pM and 100pM for SARS-CoV-2 and real SARS-CoV-2 viruses, respectively.
a transmission mirror image of SARS-CoV-2 (previously known as 2019-nCoV) from NIAID RML.
the researchers used a model of hACE2 genetically modified mice developed by Dr. Qin Chuan of the Institute of Experimental Zoology of the Chinese Academy of Medical Sciences to complete antiviral experiments in the body of the antibody.
results showed that BD-368-2 antibodies had strong therapeutic and preventive effects on SARS-CoV-2: when the BD-368-2 antibodies were injected into infected mice, the viral load was reduced by about 2,400 times;
, however, the mechanisms of the BD-368-2 antibody and SARS-CoV-2 are largely unknown.
, in a new study, the researchers reported a cryo-EM structure with a resolution of 3.5 E when combined with the SARS-CoV-2 hedgehog protein (S protein) tripolymer complex. It is revealed that BD-368-2 completely blocks the recognition of ACE2 by occupying all three subject binding domains (RBDs) at the same time, regardless of whether the RBD is in the "up" or "down" configuration.
results were published online September 14, 2020 in the journal Cell under the title "Structurally resolved SARS-CoV-2 antibody show high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy."
, BD-368-2 treated infected adult hamsters with low doses and different treatment windows, while infected hamsters treated with placebos showed severe interstitio pneumonia.
addition, the table of BD-368-2 completely avoids the recurring VH3-53/VH3-66 co-binding bits of antibodies, as confirmed by the three-way cocrystalline structure of RBD.
pairing BD-368-2 with recurring strong-effect meso-antibodies can medium the SARS-CoV-2 prosthesis at pM levels and save mutation-induced meso-escape.
, the researchers reasonably designed a new RBD table that could lead to high school and pot, and confirmed the therapeutic potential of BD-368-2 in the treatment of COVID-19.
(bioon.com) Reference: Shuo Du et al. Structurally resolved SARS-CoV-2 antibody show high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell, 2020, doi:10.1016/j.cell.2020.09.035.